Research - The American Society of Hematology’s annual meeting (56th!) begins on December 6, but abstracts from the conference will be released this morning. This, and the … Continue Reading
Read NowResearch - Trillium Therapeutics (TSX:TR) (OTC:SCTPF) is an immuno-oncology company developing novel cancer therapeutics. Trillium was founded in 2003 and went public on the Toronto exchange via … Continue Reading
Read NowResearch - Pain Therapeutics (PTIE) and Durect (DRRX) just announced that Pfizer (PFE) will discontinue development of Remoxy (Extended-Release oxycodone) and will return all rights to Pain Therapeutics. Pain Therapeutics had the rights to … Continue Reading
Read NowResearch - Bluebird bio (BLUE) develops gene therapy products for diseases with significant unmet needs. Leveraging a proprietary lentiviral gene therapy platform, Bluebird currently has three core clinical … Continue Reading
Premium: Read NowResearch - Our view is that QLT Inc's (QLTI) board will find a way to wind down the business in a favorable manner.
Read NowResearch - Late-breaking abstracts from AASLD’s upcoming The Liver Meeting were published on Tuesday morning at 10:00 AM, and a number of companies with development-stage therapeutics in the space felt the impact. … Continue Reading
Read NowResearch - Alcobra (ADHD) reported results on Monday morning from a phase 3 trial of metadoxine sustained-release in adult ADHD patients. While the company spins the results as positive based … Continue Reading
Premium: Read Now
